Moderna (MRNA) Gets Phase 3 Melanoma Vaccine Validation At ESMO And NEJM

Moderna (NasdaqGS:MRNA) and Merck reported detailed Phase 3 data for their individualized mRNA melanoma vaccine plus KEYTRUDA, intismeran, at ESMO 2026. The Phase 3 trial showed a significant reduction in disease recurrence and distant metastasis in melanoma patients receiving the combination regimen. The intismeran results have been accepted for publication in The New England Journal of Medicine, adding peer reviewed validation for the program. The mRNA melanoma vaccine and KEYTRUDA Phase 3...